Newel Health, a European HealthTech company specialized in certified digital medical devices, has received CE Class IIa certification for Amicomed, its digital therapeutic for hypertension. This regulatory milestone positions Amicomed among the leading digital therapies for hypertension management in Europe.

Amicomed enables individuals to manage their blood pressure daily via smartphone, offering personalized guidance, medication reminders, and lifestyle recommendations tailored to each user’s clinical profile. It captures real-world data and translates it into meaningful insights for both users and healthcare professionals, supporting better adherence and continuity of care.

In addition to its direct-to-consumer availability, Amicomed is used as a digital companion to antihypertensive therapies and has been validated in population health initiatives, digital insurance models, and chronic care programs — making it relevant across pharmaceutical, insurance, and healthcare systems. More info here.

Newel Health has long been part of the Frontiers Health community, contributing to the global conversation on the future of healthcare. Their insights have helped shape key sessions, including:

• Digitally Augmented Therapies—exploring how digital tools can complement and elevate traditional care. WATCH HERE
• Realizing the Potential of Digital Health—discussing consumer-grade product design user engagement as the foundation for effective health outcomes. WATCH HERE
• Beyond Parkinson’s—diving deep on the future of neurology, with the aim to advance a unified, patient-first approach to neurodegenerative disease. WATCH HERE

These contributions reflect Newel’s broader mission: to co-create a future where digital health is not just innovative but impactful—grounded in science, designed for people, and built for real-world use.

Date: June 9th, 2025^th, 2025 | Source: www.prnewswire.co.uk

Join us and our global community of health innovators in Berlin on November 11-12, 2025.

Get your pass now!